Evidence map›Paper›PMID 29738480›Full record

ReviewMaterials (Basel, Switzerland)2018

The Multifaceted Uses and Therapeutic Advantages of Nanoparticles for Atherosclerosis Research.

Nicholas DiStasio, Stephanie Lehoux, Ali Khademhosseini, Maryam Tabrizian

Abstract readReview
In one paragraph

Review in Materials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Key parameters for designing robust 2D and 3D spheroid models forBioengineering & translational medicine · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Vulnerable Plaque, Characteristics, Detection, and Potential Therapies.Journal of cardiovascular development and disease · 2019
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nicholas DiStasioBiomedical Engineering Department, McGill University, 3775 Rue University, Montréal, QC H3A 2B4, Canada. Nicholas.Distasio@mail.mcgill.ca.
Stephanie LehouxLady Davis Institute for Medical Research, Department of Medicine, McGill University, 3755 Cote Sainte Catherine, Montreal, QC H3T 1E2, Canada. Stephanie.Lehoux@mcgill.ca.
Ali KhademhosseiniDepartment of Bioengineering, Chemical Engineering, and Radiological Sciences, University of California, Los Angeles, 410 Westwood Plaza, Los Angeles, CA 90095-1600, USA. Khademh@ucla.edu.ORCID 0000-0002-2692-1524
Maryam TabrizianBiomedical Engineering Department, McGill University, 3775 Rue University, Montréal, QC H3A 2B4, Canada. Maryam.Tabrizian@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticles are uniquely suited for the study and development of potential therapies against atherosclerosis by virtue of their size, fine-tunable properties, and ability to incorporate therapies and/or imaging modalities. Furthermore, nanoparticles can be specifically targeted to the atherosclerotic plaque, evading off-target effects and/or associated cytotoxicity. There has been a wealth of knowledge available concerning the use of nanotechnologies in cardiovascular disease and atherosclerosis, in particular in animal models, but with a major focus on imaging agents. In fact, roughly 60% of articles from an initial search for this review included examples of imaging applications of nanoparticles. Thus, this review focuses on experimental therapy interventions applied to and observed in animal models. Particular emphasis is placed on how nanoparticle materials and properties allow researchers to learn a great deal about atherosclerosis. The objective of this review was to provide an update for nanoparticle use in imaging and drug delivery studies and to illustrate how nanoparticles can be used for sensing and modelling, for studying fundamental biological mechanisms, and for the delivery of biotherapeutics such as proteins, peptides, nucleic acids, and even cells all with the goal of attenuating atherosclerosis. Furthermore, the various atherosclerosis processes targeted mainly for imaging studies have been summarized in the hopes of inspiring new and exciting targeted therapeutic and/or imaging strategies.

Indexed as

atherosclerosisdrug deliveryimagingnanoparticlestargetingtherapeutic delivery

Identifiers

PMID29738480
PMCPMC5978131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.